Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRN1371 in Advanced Solid Tumors and Metastatic Urothelial Carcinoma
NCT02608125Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Oct 2015
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of prn1371 in solid tumor and urothelial carcinoma (UC), sponsored by Sanofi. Primary endpoint: Incidence of treatment related Grade 3 and/or Grade 4 adverse events (Dose Limiting Toxicities) at 28 days. Started Oct 2015; status: terminated.
02
Drugs
prn1371
03
Conditions
solid tumorurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02608125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02608125.